Highlights of This Issue 4417

SPECIAL FEATURES

CCR Translations

4419 TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal
Ramaswamy Govindan and Jason Weber
See related article, p. 4647

4422 "Companion Diagnostics": Has Their Time Come and Gone?
Fred R. Hirsch, Paul A. Bunn Jr, and Roy S. Herbst
See related article, p. 4488

CCR New Strategies

4425 New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Juliane M. Jurgensmeier, Joseph P. Eder, and Roy S. Herbst

CCR Perspectives in Drug Approval

4436 FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Molecular Pathways

4442 Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Felix Y. Feng, J. Chad Brenner, Maha Hussain, and Arul M. Chinnaiyan

CANCER THERAPY: CLINICAL

4449 Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

4459 p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
Nicola R. Hardwick, Mary Carroll, Teodora Kailcheva, Dajun Qian, Dean Lim, Lucille Leong, Peiguo Chu, Joseph Kim, Joseph Chao, Marwan Fakih, Yun Yen, Jonathan Espenschied, Joshua D.L. Ellenbogen, Don J. Diamond, and Vincent Chung

4471 Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
Jacques Medioni, Gae Deplanque, Jean-Marc Ferrero, Tristan Maurina, Jean-Michel P. Rodier, Eric Raymond, Jorge Allyon, Gerard Maruani, Pascal Houillier, Sarah Mackenzie, Stephanie Renaux, Jean-Francois Dufour-Lamartine, Reza Elaidi, Celine LeReret, and Stephane Oudard

PERSONALIZED MEDICINE AND IMAGING

4478 Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer
Christiane Amendt, Eike Staub, Manja Friese-Hamim, Stephan Storkel, and Christopher Stroh

4488 Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
See related commentary, p. 4422
Alet-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy

Zenia Saridaki, Joanne B. Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W. Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, and Sabine Teijpar

FcγRIla and FcγRIIla Polymorphisms and Cetuximab Benefit in the Microscopic Disease

Francesco Sclafani, David Gonzalez de Castro, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Jaume Capdevila, Bengt Glimelius, Susana Roselló Keränen, Andrew Wotherspoon, Gina Brown, Diana Tait, Ruwaida Begum, Janet Thomas, Jacqueline Oates, and Ian Chau

Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts


Noninvasive Detection of Glutamate Predicts Survival in Pediatric Medulloblastoma

Martin Wilson, Simrandip K. Gill, Lesley McPherson, Martin English, Theodoros N. Arvanitis, and Andrew C. Peet

Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH


The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer

Alison Backen, Andrew C. Renehan, Andrew R. Clamp, Carlo Berzuini, Cong Zhou, Amit Oza, Selina Banno, Stefan J. Scherer, Rosamonde E. Banks, Caroline Dive, and Gordon C. Jayson
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
</table>
| 4625 | Expression of Androgen and Estrogen Signaling Components and Stem Cell Markers to Predict Cancer Progression and Cancer-Specific Survival in Patients with Metastatic Prostate Cancer  
Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Kenichi Takayama, Toru Sugihara, Daisuke Obinata, Yuta Yamada, Jimpei Kumagai, Haruki Kume, Yasuyoshi Ouchi, Satoshi Inoue, and Yukio Homma |
| 4636 | miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer  
| 4647 | Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer  
Miguel A. Molina-Vila, Jordi Bertran-Alamillo, Amaya Gascó, Clara Mayo-de-las-Casas, María Sánchez-Ronco, Laia Pujantell-Pastor, Laura Bonanno, Adolfo G. Favaretto, Andrés F. Cardona, Alain Vergnenègre, Maríà Sánchez-Ronco, Bartomeu Massuti, Teresa Morán, Enric Carcereny, Santiago Viteri, and Rafael Rosell  
See related commentary, p. 4419 |
| 4660 | An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer  
Ren-Tao Wang, Meng Xu, Cheng-Xiong Xu, Zhi-Gang Song, and Hua Jin |
| 4705 | Decreased Expression of miR216a Contributes to Non–Small-Cell Lung Cancer Progression  
Daniel J. Shiwarshi, Chunbo Shao, Anke Bill, Jean Kim, Dong Xiao, Carol A. Bertrand, Raja S. Senthala, Daisuke Sano, Jeffery N. Myers, Patrick Ha, Jennifer Grandis, L. Alex Gaither, Manojkumar A. Puthenveedu, and Umamaheswar Duvvuri |
| 4717 | GSK-3β–Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion  
Hong Zhang, Wei Hou, Hua-Li Wang, Hai-Jing Liu, Xin-Ying Jia, Xing-Zheng Zheng, Yong-Xin Zou, Xin Li, Lin Hou, Michael A. McNutt, and Bo Zhang |
ABOUT THE COVER

The cover shows the crystal structure of the SAR650984-Fab in complex with human CD38 resolved at 1.53 Å resolution. A close-up view of the epitope highlights the interface between human CD38 and SAR650984-Fab, which involves mainly antibody heavy chain CDR loop H3 (yellow) and light chain CDR loops L1, L2 and L3 (green). For details, see the article by Deckert and colleagues on page 4574 of this issue.
Clinical Cancer Research

20 (17)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/17

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.